Clinical Trial Update: First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks [Phase 3]

View source ↗

Summary

Phase 3 trial update on secukinumab delivered via pre-filled syringes for chronic plaque-type psoriasis with completed results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Plaque-type

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Moderate to Severe Plaque-type Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2018-08-08